Adcytherix

Biotech & Life Sciences · Marseille, France · Founded 2023

Innovative antibody drug conjugates targeting high unmet need diseases like cancer MoreLess

Adcytherix is a biopharmaceutical company specializing in the development of novel antibody drug conjugates (ADCs) aimed at treating high unmet need diseases, particularly cancer. The company operates in the biopharmaceutical market and serves healthcare providers, researchers, and patients who require advanced cancer treatments. Adcytherix's business model revolves around research and development, leveraging a seasoned management team and a network of world-leading experts in ADC development. The company is financially backed by prominent life science investors including Pontifax, Pureos Bioventures, RA Capital Management, and Dawn Biopharma, a platform controlled by KKR. Revenue is primarily generated through partnerships, licensing agreements, and potentially future sales of their ADC products. Keywords: biopharmaceutical, antibody drug conjugates, cancer treatment, high unmet need, research and development, healthcare, life science investors, oncology, innovative therapies, ADC development.

Valuation $100–500M

Headcount <100

Total funding $100–500M

Unlock exact values

Company overview

Adcytherix company information

The essential company record, classifications and operating signals in one place.

Status: Operational
Founded: 2023
Headquarters: Marseille, France
Employees: 24
Open positions: None listed
Dealroom signal: 92.2

Website ↗LinkedIn ↗

client focusb2bsub industryBioTechnologybusiness modelManufacturingindustryHealthsectorBiotechnologysectorbiotech medtech and e-healthsectorObservatoire Deeptechsectorparticipations bpifrancesectorradar de l'innovationsectorobservatoire industrial techsectorDT and LSsectorobservatoire healthtechsectorscience-based

Valuation & funding

Adcytherix funding history

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES AOther financing	Oct 2025	$116M	$462M	aMoon Fund · Surveyor Capital · Dawn Biopharma · Bpifrance	↗
SEEDOther financing	Jun 2024	$33M	$132M	Dawn Biopharma · RA Capital Management · Pureos Bioventures · Pontifax Funds	↗

Showing 2 recorded eventsUnlock the complete deal history →

Growth signals

Adcytherix website traffic

Latest recorded traffic for Adcytherix is 350 monthly website visits, down 73.1% over the last three months. Adcytherix's team grew 50% over the past year.

Latest monthly visits350 3-month web change-73.1% 1-year team growth+50%

Monthly website visits15 observations · Jun 2024–Jun 2026

Hover or focus a point to see its exact monthly valueCompare with peers →

Comparisons

Adcytherix compared with similar companies

Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DIDillicoA revolutionary approach to the scale-up and production of mRNA-based vaccine and therapeutics	Meylan, France	Operational	15	$9.3M	$33M
BIBiomemoryProvides biodigital data storage for large companies and administrations	Paris, France	Operational
MEMexBrainDialysis-based medical device for targeted metal extraction.	Villeurbanne, France	Operational
ETEgle TherapeuticsEgle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones	Paris, France	Operational
CTCyllene TherapeuticsNon-replicating HSV-1 gene therapy for neurological diseases.	Paris, France	Operational
HEHealshapePersonalized, resorbable bioprosthesis for natural breast reconstruction	Nantes, France	Operational
HAHawkCellProvides magnetic resonance imaging services to healthcare professionals	Lyon, France	Operational
TRTridek-OneDeveloping a novel CD31 agonist approach to modulate immune activation and so provide a new way to manage inflammatory conditions	Paris, France	Operational

Showing 8 of the closest matchesCompare every metric →

Talent graph

Adcytherix's talent

Book a demo to see the people

Team profiled 4 named & role-tagged

Founders /100 quality score

Key operators 3 quality /100

Potential founders likely future founders

Startup mafia alumni-founded startups

Talent movements in · out past 12 months

Source: Dealroom Talent Intelligence.

Investors

10 investors on Adcytherix's cap table

Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.

Seed 4 investors entered at this stage

Pontifax Funds

Dawn Biopharma

RA Capital Management

Pureos Bioventures

Series A 6 investors entered at this stage

Bpifrance

Andera Partners

Kurma Partners

Angelini Ventures

aMoon Fund

Surveyor Capital

Global footprint

Where Adcytherix has talent and traffic

Workforce by country

6 countries with
team presence

🇫🇷 France57.9%

🇺🇸 United States15.8%

🇳🇱 Netherlands10.5%

🇮🇪 Ireland5.3%

🇬🇧 United Kingdom5.3%

Top 5 of 6 shown

In the news

Latest news about Adcytherix

Recent press, funding announcements, and product moves mentioning Adcytherix — open to read from the original sources.

See all news

Market sentiment

What the market is saying about Adcytherix

An AI-synthesized read of the highest-engagement posts about Adcytherix on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Adcytherix’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Request a free trial

Takes under a minute. Already use Dealroom? Log in.